Literature DB >> 32319079

Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma.

L Tao1, S Wang2, L Yang3, L Jiang3, J Li4, X Wang3.   

Abstract

Major histocompatibility complex class I (MHC-I)-dependent inhibitory receptors on natural killer (NK) cells have been found to contribute to NK cell dysfunction in hepatocellular carcinoma (HCC). However, the roles of MHC-I-independent inhibitory receptors on NK cells in HCC remain poorly defined. In this study, we analyzed the expression of the MHC-I-independent inhibitory receptors sialic acid-binding immunoglobulin-like lectin (Siglec)-7 and Siglec-9 on NK cells by analyzing the peripheral blood of 35 HCC patients and 63 healthy donors. We observed that HCC patients had lower frequencies and total numbers of NK cells in the peripheral blood. Importantly, both the expression levels of Siglec-7 on NK cells and the frequencies of Siglec-7+ NK cells were significantly reduced in HCC patients, which was accompanied by a decrease in activating receptor and an increase in inhibitory receptor expression on NK cells. Moreover, Siglec-7+ NK cells expressed higher levels of activating receptors and displayed stronger effector functions, compared with Siglec-7- NK cells. Our findings demonstrate for the first time that reduced Siglec-7 expression predicts NK cell dysfunction in HCC patients, suggesting that Siglec-7 may be a potential marker of functional NK cell subset in HCC patients.
© 2020 British Society for Immunology.

Entities:  

Keywords:  Siglec-7; hepatocellular carcinoma; natural killer cells

Mesh:

Substances:

Year:  2020        PMID: 32319079      PMCID: PMC7366747          DOI: 10.1111/cei.13444

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  42 in total

1.  A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues. A comparison with Siglec-9.

Authors:  Toshiyuki Yamaji; Takane Teranishi; Magnus S Alphey; Paul R Crocker; Yasuhiro Hashimoto
Journal:  J Biol Chem       Date:  2001-12-10       Impact factor: 5.157

2.  High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer.

Authors:  Cheng Sun; Jing Xu; Qiang Huang; Mei Huang; Hao Wen; Chuanshan Zhang; Jinyu Wang; Jiaxi Song; Meijuan Zheng; Haoyu Sun; Haiming Wei; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

Review 3.  Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy.

Authors:  Zachary J Brown; Tim F Greten; Bernd Heinrich
Journal:  Hepatology       Date:  2019-09-19       Impact factor: 17.425

4.  Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes.

Authors:  G Nicoll; J Ni; D Liu; P Klenerman; J Munday; S Dubock; M G Mattei; P R Crocker
Journal:  J Biol Chem       Date:  1999-11-26       Impact factor: 5.157

Review 5.  Siglecs and immune regulation.

Authors:  Shiv Pillai; Ilka Arun Netravali; Annaiah Cariappa; Hamid Mattoo
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

6.  Siglec-7: a sialic acid-binding lectin of the immunoglobulin superfamily.

Authors:  T Angata; A Varki
Journal:  Glycobiology       Date:  2000-04       Impact factor: 4.313

7.  Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells.

Authors:  Yoshihide Kawasaki; Akihiro Ito; Donald A Withers; Takenobu Taima; Narihiko Kakoi; Seiichi Saito; Yoichi Arai
Journal:  Glycobiology       Date:  2010-07-27       Impact factor: 4.313

8.  Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.

Authors:  Bastian Hoechst; Torsten Voigtlaender; Lars Ormandy; Jaba Gamrekelashvili; Fei Zhao; Heiner Wedemeyer; Frank Lehner; Michael P Manns; Tim F Greten; Firouzeh Korangy
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

9.  CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.

Authors:  Amira A Barkal; Rachel E Brewer; Maxim Markovic; Mark Kowarsky; Sammy A Barkal; Balyn W Zaro; Venkatesh Krishnan; Jason Hatakeyama; Oliver Dorigo; Layla J Barkal; Irving L Weissman
Journal:  Nature       Date:  2019-07-31       Impact factor: 49.962

10.  Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy.

Authors:  Jun Wang; Jingwei Sun; Linda N Liu; Dallas B Flies; Xinxin Nie; Maria Toki; Jianping Zhang; Chang Song; Melissa Zarr; Xu Zhou; Xue Han; Kristina A Archer; Thomas O'Neill; Roy S Herbst; Agedi N Boto; Miguel F Sanmamed; Solomon Langermann; David L Rimm; Lieping Chen
Journal:  Nat Med       Date:  2019-03-04       Impact factor: 53.440

View more
  8 in total

Review 1.  Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives.

Authors:  Nicolas Jacquelot; Cyril Seillet; Fernando Souza-Fonseca-Guimaraes; Adrian G Sacher; Gabrielle T Belz; Pamela S Ohashi
Journal:  Int J Mol Sci       Date:  2021-08-22       Impact factor: 5.923

Review 2.  Sialic Acids and Their Influence on Human NK Cell Function.

Authors:  Philip Rosenstock; Thomas Kaufmann
Journal:  Cells       Date:  2021-01-29       Impact factor: 6.600

3.  Modulation of Siglec-7 Signaling Via In Situ-Created High-Affinity cis-Ligands.

Authors:  Senlian Hong; Chenhua Yu; Emily Rodrigues; Yujie Shi; Hongmin Chen; Peng Wang; Digantkumar G Chapla; Tao Gao; Ruoxuan Zhuang; Kelley W Moremen; James C Paulson; Matthew S Macauley; Peng Wu
Journal:  ACS Cent Sci       Date:  2021-08-13       Impact factor: 14.553

4.  PD-1 blockade improves the anti-tumor potency of exhausted CD3+CD56+ NKT-like cells in patients with primary hepatocellular carcinoma.

Authors:  Longxiang Tao; Shanshan Wang; Guijie Kang; Shanyue Jiang; Wenwei Yin; Lu Zong; Jing Li; Xuefu Wang
Journal:  Oncoimmunology       Date:  2021-11-09       Impact factor: 8.110

Review 5.  Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma.

Authors:  Felix Marsh-Wakefield; Angela L Ferguson; Ken Liu; Cositha Santhakumar; Geoffrey McCaughan; Umaimainthan Palendira
Journal:  Ther Adv Med Oncol       Date:  2022-07-22       Impact factor: 5.485

Review 6.  Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.

Authors:  Elena Gianchecchi; Andrea Arena; Alessandra Fierabracci
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

7.  Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia.

Authors:  Caroline Duault; Anil Kumar; Adeleh Taghi Khani; Sung June Lee; Lu Yang; Min Huang; Christian Hurtz; Bryan Manning; Lucy Ghoda; Tinisha McDonald; Norman J Lacayo; Kathleen M Sakamoto; Martin Carroll; Sarah K Tasian; Guido Marcucci; Jianhua Yu; Michael A Caligiuri; Holden T Maecker; Srividya Swaminathan
Journal:  Blood       Date:  2021-10-21       Impact factor: 25.476

Review 8.  Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry.

Authors:  Benjamin Shibru; Katharina Fey; Stephan Fricke; André-René Blaudszun; Friederike Fürst; Max Weise; Sabine Seiffert; Maria Katharina Weyh; Ulrike Köhl; Ulrich Sack; Andreas Boldt
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.